The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Clinical decision tool for guiding outpatient vs inpatient bispecific antibody therapy in myeloma
Shahzad Raza, MD, Cleveland Clinic, Cleveland, OH, shares insight into a clinical decision tool to guide outpatient versus inpatient bispecific antibody therapy in patients with multiple myeloma, highlighting the use of artificial intelligence tools to predict therapy-related complications. Dr Raza explains that a scoring system can assess various factors and guide clinicians in deciding which patients can be safely managed as outpatients and which require hospitalization. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We actually use the artificial intelligence tools to come up with all those criteria where the patients can have complications like cytokine release syndrome, ICANS, and we actually predict them into the machine learning algorithms. What we find out, the distance to the healthcare facility, that’s number one criteria that we have been seeing as challenging, especially all the patients who have comorbidities, difficult to access to the main center, it’s the number one...
We actually use the artificial intelligence tools to come up with all those criteria where the patients can have complications like cytokine release syndrome, ICANS, and we actually predict them into the machine learning algorithms. What we find out, the distance to the healthcare facility, that’s number one criteria that we have been seeing as challenging, especially all the patients who have comorbidities, difficult to access to the main center, it’s the number one. Number two is the disease status. If somebody is crashing, has an aggressive disease, and we know that they are at a higher risk of CRS, those do benefit from inpatient hospitalizations. So you actually score them. Each has a category to score them. And then if your score is higher, then the clinicians will have an idea like who needs to get admitted and who needs to be managed as an outpatient. If somebody has a low score, you can manage them safely as an outpatient. But if somebody has a high score, lack of caregiver, distance, disease characteristics, those are the patients that require hospitalization. It’s important that we should have a step-up dosing because of the guidelines, but it will help us because more and more academic centers are starting to do this as an outpatient. That will be an encouraging sign. And what will happen is that the community centers will learn from academic centers and how they are doing it. At our centers, we’ve been doing this as an outpatient and trying to get these patients treated as outpatients, people learn from experience, and that’s how we did it, and how many patients have complications, so then I think you can imply those things into their best practices as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
